Replimune Group Inc. (REPL)

Business: Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer.

IPO Date: 20-Jul-2018

CEO & Director: Mr. Philip Astley-Sparke FSA

Founder, Pres, Chief R&D Officer and Director: Dr. Robert Coffin Ph.D.

Listing: NASDAQ: REPL

Country: United States

Headquarters: Woburn, MA

Website: https://www.replimune.com

Market cap: $901.91 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-118.04 Mln

Cash: $395.66 Mln

Total Debt: $32.84 Mln

Insider's Holding: 9.18%

Liquidity: Low

52 Week range: $13.06 - 39.84

Shares outstanding: 49,070,000

6 Years Aggregate:

• CFO: $-252.59 Mln
• EBITDA: $-304.04 Mln
• Net Profit: $-309.77 Mln